Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEED trial of ipragliflozin for endothelial dysfunction in type 2 diabetes and chronic kidney disease
jRCTs071190054Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ipragliflozin in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and endothelial dysfunction (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change in reactive hyperemia index. Started Mar 2020; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)endothelial dysfunction
Beyond the preview
Go deeper on jRCTs071190054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190054.